Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1230P - Risk of cancer in patients with Behçet's disease: A Mendelian randomization study

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Haoxin Peng

Citation

Annals of Oncology (2020) 31 (suppl_4): S735-S743. 10.1016/annonc/annonc282

Authors

H. Peng1, X. Wu1, Y. Wen1, C. Li2, H. Liang2, W. Liang2, J. He2

Author affiliations

  • 1 Nanshan College, Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., 510000 - Guangzhou/CN
  • 2 Department Of Thoracic Oncology And Surgery, The First Affiliated Hospital Of Guangzhou Medical University, Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., 510000 - Guangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1230P

Background

Epidemiology evidences have demonstrated that Behçet's disease (BD) may be associated with increased risk of several types of cancer. However, conventional observational studies are susceptible to potential confounders and inverse causation. In addition, the causal effects between BD and cancers remain unknown.

Methods

11 single nucleotide polymorphisms (SNPs) in BD were identified as reaching genome-wide significance (p < 5×10-8) and were thus retrieved from latest published genome-wide association studies (GWASs). Available genetic data on different types of cancer were extracted from several consortia or published studies, including the International Lung Cancer Consortium (ILCCO, 11, 348 cases and 15, 861 controls), Breast Cancer Association Consortium (BCAC, 122, 977 cases and 105, 974 controls) and so on. With two-sample Mendelian randomization (MR) analysis, study-specific estimates were summarized using inverse-variance-weighted (IVW), weighted median and MR-Egger methods. MR-Egger regression was conducted to evaluate the pleiotropy. Leave-one-out analysis was employed to appraise whether the MR estimate was biased by a single SNP.

Results

MR analysis indicated that BD patients were at lower risks of lung cancer (OR = 0.972, 95% CI: 0.947-0.996, p = 0.024), tongue cancer (OR = 0.999, 95% CI: 0.999-1.000, p = 0.004), penile cancer (OR = 0.999, 95% CI: 0.999-1.000, p = 0.030) and brain cancer (OR = 0.999, 95% CI: 0.999-1.000, p = 0.035) (Table). MR-Egger regression suggested the absence of directional horizontal pleiotropy. Leave-one-out results shown that by omitting the included 11 SNPs singly, no individual genetic variants appeared to have any significant effect on the overall results. Table: 1230P

Mendelian randomization estimates of the causal effect of genetically Behçet's disease on different types of cancer

Cancer type IVW MR-Egger Weighted median
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Lung cancer 0.972 (0.947, 0.996) 0.024 0.955 (0.921, 0.951) 0.050 0.963 (0.938, 0.998) 0.004
Breast cancer 0.996 (0.987, 1.005) 0.383 0.998 (0.982, 1.013) 0.773 0.997 (0.987, 1.006) 0.480
Tongue cancer 0.999 (0.999, 1.000) 0.004 1.000 (1.000, 1.000) 0.097 1.000 (1.000, 1.000) 0.004
Penile cancer 0.999 (0.999, 1.000) 0.030 1.000 (1.000, 1.000) 0.160 1.000 (1.000, 1.000) 0.807
Brain cancer 0.999 (0.999, 1.000) 0.035 1.000 (0.999, 1.000) 0.163 0.999 (0.999, 1.000) 0.075

Conclusions

BD was causally correlated with reduced risk of lung cancer, brain cancer, tongue cancer and penile cancer, suggesting autoimmune or autoinflammatory etiopathology associated with BD activity might play a role in the suppression of cancer development.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

China National Science Foundation (Grant No. 81871893); Key Project of Guangzhou Scientific Research Project (Grant No. 201804020030); Cultivation of Guangdong College Students' Scientific and Technological Innovation (“Climbing Program” Special Funds) (Grant No. pdjh2020a0480).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.